Literature DB >> 10692045

Characterization and role in experimental systemic lupus erythematosus of T-cell lines specific to peptides based on complementarity-determining region-1 and complementarity-determining region-3 of a pathogenic anti-DNA monoclonal antibody.

N Brosh1, E Eilat, H Zinger, E Mozes.   

Abstract

Peptides based on the complementarity-determining region 1 (CDR1) and CDR3 of an anti-DNA monoclonal antibody (mAb) carrying the 16/6 idiotype (Id) were shown to induce experimental systemic lupus erythematosus (SLE) in susceptible mouse strains. In the present study, T-cell lines specific to the pCDR1 and pCDR3 peptides were established in BALB/c and in SJL mice, respectively. The T-cell lines were characterized and analysed for their pathogenicity upon administration to syngeneic mouse strains. Both T-cell lines expressed the alphabeta T-cell receptor (TCR) and the CD4+ CD8- phenotype. Additionally, both cell lines secreted interleukin (IL)-4 and IL-10 upon stimulation with their specific peptide, thus belonged to the T helper 2 (Th2) subset. Upon immunization, the pCDR3-specific T-cell line induced experimental SLE in SJL mice. The animals produced high levels of autoimmune anti-DNA and antinuclear protein antibodies, as well as anti-16/6 Id antibodies (Abs). Furthermore, the mice developed clinical manifestations, including leukopenia, proteinuria and accumulation of immune complex deposits in their kidneys. The pCDR1-specific T-cell line failed to induce SLE when injected into BALB/c mice. It is thus suggested that pCDR3 is an immunodominant epitope in experimental SLE and that pCDR3-specific T cells initiate autoimmunity, leading to SLE, probably via epitope spreading.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10692045      PMCID: PMC2327144          DOI: 10.1046/j.1365-2567.2000.00957.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  26 in total

Review 1.  Immune focusing vs diversification and their connection to immune regulation.

Authors:  E E Sercarz
Journal:  Immunol Rev       Date:  1998-08       Impact factor: 12.988

Review 2.  New experimental autoimmune models.

Authors:  E Mozes; S Brocke; H Fricke; M Dayan; Y Shoenfeld; S Mendlovic
Journal:  Isr J Med Sci       Date:  1989-12

3.  Administration of monoclonal anti-T cell antibodies retards murine lupus in BXSB mice.

Authors:  D Wofsy
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

Review 4.  Murine models of systemic lupus erythematosus.

Authors:  A N Theofilopoulos; F J Dixon
Journal:  Adv Immunol       Date:  1985       Impact factor: 3.543

5.  Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein.

Authors:  A Ben-Nun; H Wekerle; I R Cohen
Journal:  Nature       Date:  1981-07-02       Impact factor: 49.962

6.  T cell lines specific for an immunodominant epitope of human basic protein define an encephalitogenic determinant for experimental autoimmune encephalomyelitis-resistant LOU/M rats.

Authors:  G Hashim; A A Vandenbark; D P Gold; T Diamanduros; H Offner
Journal:  J Immunol       Date:  1991-01-15       Impact factor: 5.422

Review 7.  Pathogenic idiotypes of autoantibodies in autoimmunity: lessons from new experimental models of SLE.

Authors:  Y Shoenfeld; E Mozes
Journal:  FASEB J       Date:  1990-06       Impact factor: 5.191

8.  The role of anti-idiotypic antibodies in the induction of experimental systemic lupus erythematosus in mice.

Authors:  S Mendlovic; H Fricke; Y Shoenfeld; E Mozes
Journal:  Eur J Immunol       Date:  1989-04       Impact factor: 5.532

9.  Direct binding of a myasthenia gravis related epitope to MHC class II molecules on living murine antigen-presenting cells.

Authors:  E Mozes; M Dayan; E Zisman; S Brocke; A Licht; I Pecht
Journal:  EMBO J       Date:  1989-12-20       Impact factor: 11.598

10.  Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4.

Authors:  D Wofsy; W E Seaman
Journal:  J Exp Med       Date:  1985-02-01       Impact factor: 14.307

View more
  5 in total

1.  Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients.

Authors:  N Mauermann; Z Sthoeger; H Zinger; E Mozes
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

2.  T cell help is required to induce idiotypic-anti-idiotypic autoantibody network after immunization with complementary epitope 289-308aa of La/SSB autoantigen in non-autoimmune mice.

Authors:  M G Papamattheou; J G Routsias; E E Karagouni; C Sakarellos; M Sakarellos-Daitsiotis; H M Moutsopoulos; A G Tzioufas; E N Dotsika
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

3.  Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies.

Authors:  Z M Sthoeger; M Dayan; A Tcherniack; L Green; S Toledo; R Segal; O Elkayam; E Mozes
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

Review 4.  Humanized Mouse Models of Systemic Lupus Erythematosus: Opportunities and Challenges.

Authors:  Jiaxuan Chen; Shuzhen Liao; Huimin Zhou; Lawei Yang; Fengbiao Guo; Shuxian Chen; Aifen Li; Quanren Pan; Chen Yang; Hua-Feng Liu; Qingjun Pan
Journal:  Front Immunol       Date:  2022-01-18       Impact factor: 7.561

Review 5.  Structure-based approaches to inhibition of erbB receptors with peptide mimetics.

Authors:  Alan Berezov; Mark I Greene; Ramachandran Murali
Journal:  Immunol Res       Date:  2003       Impact factor: 4.505

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.